SPECIAL GOVERNMENT EMPLOYEES (Voting)

DEPARTMENT OF HEALTH AND HUMAN SERVICES

FOOD AND DRUG ADMINISTRATION

CENTER FOR DRUG EVALUATION AND RESEARCH

CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE

96^th Meeting

April 12, 2002

Holiday Inn, Silver Spring, MD

NDA 20-386/S028, Cozaar™ (losartan potassium), Merck and Company, Inc.

Proposed Indication: for the treatment of type II diabetic patients with nephropathy

Special Government Employees/Consultants (voting)

Jeffrey B. Kopp, M.D.

Senior Investigator

Kidney Disease Section, Metabolic Diseases Branch

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institutes of Health (NIH)

Bldg. 10, Rm. 3N116

Bethesda, MD 20892-1268

Andrew S. Brem, M.D.

Professor in Pediatrics

Brown University School of Medicine

Director, Division of Pediatric Nephrology

Rhode Island Hospital

593 Eddy Street

Providence, RI 02902